PTC THERAPEUTICS INC. news, videos and press releases - Page 4
For more news please use our advanced search feature.
PTC THERAPEUTICS INC. - More news...
PTC THERAPEUTICS INC. - More news...
- Preliminary Results Presented at ASCO Demonstrated Promising Clinical Efficacy with Unesbulin in Leiomyosarcoma Study
- FDA Approves Label Extension for Evrysdi® for Infants with Spinal Muscular Atrophy Under 2 Months Old
- PTC Therapeutics Receives Positive CHMP Opinion for Upstaza™ for the Treatment of AADC Deficiency
- PTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial Results
- PTC Therapeutics to Participate at Upcoming Investor Conferences
- PTC Therapeutics to Host Conference Call to Discuss First Quarter 2022 Financial Results
- PTC Therapeutics Provides Update on EMA Regulatory Review Timeline For Its AADC Deficiency Gene Therapy Program
- PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- PTC Therapeutics Announces Initiation of PIVOT-HD Phase 2 Clinical Trial to Evaluate PTC518 in Patients with Huntington's Disease
- PTC Therapeutics to Present New Data at the 2022 Muscular Dystrophy Association Clinical & Scientific Conference
- PTC Therapeutics to Participate at Upcoming Investor Conferences
- PTC Therapeutics Provides a Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
- PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2021 Financial Results
- FDA Grants Evrysdi® Priority Review Based on Results From Treating Pre-Symptomatic Infants with Spinal Muscular Atrophy
- PTC Therapeutics Announces Launch of 8th Annual STRIVE™ Awards Program to Fund Initiatives Benefitting the Duchenne Muscular Dystrophy Community
- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- PTC Therapeutics Announces Launch of 2022 Global Talent Pipeline Program
- PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 40th Annual J.P. Morgan Healthcare Conference
- Waylivra™ Receives Innovative Drug Category Pricing to Treat Familial Chylomicronemia Syndrome in Brazil
- PTC Therapeutics to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference
- Oral Splicing Modifiers that Systemically Lower Huntington Disease Protein Discovered Through PTC Therapeutics' Innovative Splicing Platform
- Evrysdi® Distinguished by Two Prestigious Awards for Outstanding Innovation in Drug Discovery
- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- PTC Therapeutics to Participate at Upcoming Virtual Investor Conference
- PTC Therapeutics Provides a Corporate Update and Reports Third Quarter 2021 Financial Results
- PTC Therapeutics to Participate at Upcoming Virtual Investor Conference
- PTC Announces Expansion of Translarna™ Label to Include Ambulatory Patients as Young as 2 Years Old in Brazil
- PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2021 Financial Results
- PTC Therapeutics Celebrates Opening of Gene Therapy Manufacturing Facility
- Tegsedi® Receives Innovative Drug Category Pricing in Brazil